Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer

Ravi A. Madan, Fatima H. Karzai, Yang Min Ning, Bamidele A. Adesunloye, Xuan Huang, Nancy Harold, Anna Couvillon, Guinevere Chun, Lisa Cordes, Tristan Sissung, Shaunna L. Beedie, Nancy A. Dawson, Marc R. Theoret, David G. McLeod, Inger Rosner, Jane B. Trepel, Min Jung Lee, Yusuke Tomita, Sunmin Lee, Clara ChenSeth M. Steinberg, Philip M. Arlen, James L. Gulley, William D. Figg*, William L. Dahut

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences